The tumor therapy landscape of synthetic lethality
Synthetic lethality is emerging as an important cancer therapeutic paradigm, while the comprehensive selective treatment opportunities for various tumors have not yet been explored. We develop the Synthetic Lethality Knowledge Graph (SLKG), presenting the tumor therapy landscape of synthetic lethality (SL) and synthetic dosage lethality (SDL). SLKG integrates the large-scale entity of different tumors, drugs and drug targets by exploring a comprehensive set of SL and SDL pairs. The overall therapy landscape is prioritized to identify the best repurposable drug candidates and drug combinations with literature supports, in vitro pharmacologic evidence or clinical trial records. Finally, cladribine, an FDA-approved multiple sclerosis treatment drug, is selected and identified as a repurposable drug for treating melanoma with CDKN2A mutation by in vitro validation, serving as a demonstrating SLKG utility example for novel tumor therapy discovery. Collectively, SLKG forms the computational basis to uncover cancer-specific susceptibilities and therapy strategies based on the principle of synthetic lethality.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Nature communications - 12(2021), 1 vom: 24. Feb., Seite 1275 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhang, Biyu [VerfasserIn] |
---|
Links: |
---|
Themen: |
47M74X9YT5 |
---|
Anmerkungen: |
Date Completed 03.03.2021 Date Revised 12.03.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41467-021-21544-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321859464 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321859464 | ||
003 | DE-627 | ||
005 | 20231225180804.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41467-021-21544-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1072.xml |
035 | |a (DE-627)NLM321859464 | ||
035 | |a (NLM)33627666 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhang, Biyu |e verfasserin |4 aut | |
245 | 1 | 4 | |a The tumor therapy landscape of synthetic lethality |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.03.2021 | ||
500 | |a Date Revised 12.03.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Synthetic lethality is emerging as an important cancer therapeutic paradigm, while the comprehensive selective treatment opportunities for various tumors have not yet been explored. We develop the Synthetic Lethality Knowledge Graph (SLKG), presenting the tumor therapy landscape of synthetic lethality (SL) and synthetic dosage lethality (SDL). SLKG integrates the large-scale entity of different tumors, drugs and drug targets by exploring a comprehensive set of SL and SDL pairs. The overall therapy landscape is prioritized to identify the best repurposable drug candidates and drug combinations with literature supports, in vitro pharmacologic evidence or clinical trial records. Finally, cladribine, an FDA-approved multiple sclerosis treatment drug, is selected and identified as a repurposable drug for treating melanoma with CDKN2A mutation by in vitro validation, serving as a demonstrating SLKG utility example for novel tumor therapy discovery. Collectively, SLKG forms the computational basis to uncover cancer-specific susceptibilities and therapy strategies based on the principle of synthetic lethality | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a CDKN2A protein, human |2 NLM | |
650 | 7 | |a Cyclin-Dependent Kinase Inhibitor p16 |2 NLM | |
650 | 7 | |a Cladribine |2 NLM | |
650 | 7 | |a 47M74X9YT5 |2 NLM | |
700 | 1 | |a Tang, Chen |e verfasserin |4 aut | |
700 | 1 | |a Yao, Yanli |e verfasserin |4 aut | |
700 | 1 | |a Chen, Xiaohan |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Chi |e verfasserin |4 aut | |
700 | 1 | |a Wei, Zhiting |e verfasserin |4 aut | |
700 | 1 | |a Xing, Feiyang |e verfasserin |4 aut | |
700 | 1 | |a Chen, Lan |e verfasserin |4 aut | |
700 | 1 | |a Cai, Xiang |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Zhiyuan |e verfasserin |4 aut | |
700 | 1 | |a Sun, Shuyang |e verfasserin |4 aut | |
700 | 1 | |a Liu, Qi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 12(2021), 1 vom: 24. Feb., Seite 1275 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:24 |g month:02 |g pages:1275 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-021-21544-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2021 |e 1 |b 24 |c 02 |h 1275 |